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Objectives: A correlation exists between breast cancer and thyroid disorders, which are com-
mon in elderly women. Thyroid hormones are degraded into trace amines, which can bind to 
the G-protein-coupled receptor trace amine-associated receptor 1 (TAAR1) and thereby activate 
it. The transformation of thyroid hormones into trace amines is carried out by the ornithine 
decarboxylase. Previously, we showed that TAAR1 overexpression (IRS ≥6) was associated with 
a significantly longer OS in primary breast cancer patients during a long-term follow-up of up 
to 14 years. Aim of the present study was to analyze the regulation of TAAR1 in breast cancer 
cell lines and the influence of triiodothyronine (T
3
), thyronamines, and tetraiodothyroacetic acid 
(Tetrac) on the expression of TAAR1 in breast cancer cells.
Methods: The effect of T
3
, thyronamines, and Tetrac on the expression of TAAR1 in breast cancer 
cell lines MCF-7 and T47D was analyzed via PCR and Western blot. A MTT assay was performed 
to test the metabolic cell viability. A scratch assay was performed to analyze cell migration.
Results: Stimulation of MCF-7 cells with 10 nM 3-iodothyronamine (T
1
AM) significantly 
increased TAAR1 protein expression (P=0.008). In T47D cells, TAAR1 expression was sig-
nificantly upregulated after the addition of 10 µg/mL estradiol to 10 nM T
1
AM (P=0.008). A 
significant (P=0.028) reduction in MCF-7 cell viability through the incubation with T
1
AM 
could be detected. Cell migration of MCF cells was significantly reduced through incubation 
with 10 nM T
1
AM.
Conclusion: A significant upregulation of TAAR1 induced by stimulation with T
1
AM may be 
a sign for an increased decarboxylation of thyroid hormones in breast cancer cells. In addition, 
there seems to be an influence of estradiol for the T
1
AM-induced upregulation of TAAR1 in 
T47D cells. TAAR1-related cell transduction mechanisms seem to be an interesting target for 
endocrine treatment options of breast cancer patients.
Keywords: breast cancer, TAAR1, 3-iodothyronamine, Tetrac, MCF7, T47D
Introduction
Breast cancer is the most common malignant tumor in women worldwide.1 In 2012, 
about 1.7 million patients worldwide were diagnosed with breast cancer and almost half 
a million people died from it.2,3 There is evidence that a correlation exists between breast 
cancer and thyroid disorders, and patients with thyroid dysfunctions have higher breast 
cancer incidences in comparison to healthy women.4–6 The specific role of thyroidal hor-
mones in breast cancer is still unclear, and future investigations are required to clarify 
it.7 Thyrotrophin (TSH) and fT
4
 levels seem to be predictive for therapeutic response and 
prognosis of patients with recurrent breast cancer.8 Ditsch et al9 observed that blood levels 
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thyroidal peroxidase are significantly elevated at the time of 
primary diagnosis in breast cancer patients. Especially in elderly 
women, those thyroid markers show a thyroid disorder.10
In our study, we investigated the influence of thyroid hor-
mones and their degradation products on breast cancer cells. 
Dysfunction of the thyroid gland is common in elderly women,10 
especially after the menopause.11–13 The highest occurrence of 
hypothyroidism and cancer of the thyroid gland takes place in 
postmenopausal women.13 The occurrence of dysfunction is 
5–20 times higher in women than in men.13 Alternation in the 
amount of thyroid hormones is associated with aging. Espe-
cially TSH and thyroid antibodies are increasing in women 
over the age of 45 years.10 Thyroid hormones influence normal 
breast cell differentiation as well as breast cancer cell prolifera-
tion. Thyroid hormones in general stimulate the angiogenesis 
of various cancer cells. Thyroid dysfunctions, especially high 
levels of fT4 or antibodies, are associated with the development 
of breast cancer. In a previous study, it could be shown that tri-
iodothyronine (T
3
) levels are positively related to the incidence 
of breast cancer in postmenopausal women.11
Thyroid hormones are degraded into trace amines (TAs), 
also referred to as thyronamines or endogenous amines.14 The 
enzyme ornithine decarboxylase (ODC) is a rate-limiting 
enzyme for the biosynthesis of polyamines, and it is probably 
responsible for the transformation of thyroid hormones into 





AM) through a deiodization process and a decarboxylation 
process.15 Compared to classical thyroid hormones, which act 
epigenetically, decarboxylated thyroid hormones are able to act 
through rapid actions such as rapid lowering of body tempera-
ture and heart rate.16 T
1





are able to modify the brain, heart, pancreatic islets, and other 
tissues via the trace amine-associated receptor 1 (TAAR1),15 
which is a G-protein-coupled receptor.16 Upon activation of 
adenyl cyclase, TAAR1 leads to a rise of the intracellular cAMP 
level.13,14 TAAR1 is expressed by various tissues including 
breast, cancer tissue, placenta, brain, spinal cord, stomach, 
pancreatic β cells, and immune cells such as macrophages, leu-
kocytes, and dendritic cells.17–20 Different compounds, including 
adrenergic, dopaminergic, and serotonergic classes, and a wide 
spectrum of agonists can activate TAAR1.21–23
TAAR1 has mostly been investigated in the neurological 
field, and it was shown that TAAR1 is able to modulate the 
serotonergic and dopaminergic systems in the brain.17 Current 
clinical studies analyze TAAR1 in schizophrenia and other 
psychiatric disorders.24 The TAAR1 agonist T
1
AM is being 
tested in numerous experimental animal studies including 
its cardiac effects, prevention of ischemia-associated insults 
such as strokes, and many other functions.21,22
In a recently published study, we analyzed the regulation 
of TAAR1 in tumor tissue of primary breast cancer patients 
(M0) and identified that TAAR1 is an independent predictor 
for OS in early breast cancer.20 TAAR1 overexpression (IRS 
≥6) was associated with a significantly longer OS in primary 
breast cancer patients (P=0.02) during long-term follow-up 
of up to 14 years.20 Therefore, TAAR1 has a favorable effect 
on OS in early breast cancer.20
The aim of our present study was to analyze the influence 
of thyronamines and T
3
 on TAAR1 expression in different 
breast cancer cells and to assess its influence on the viability 
and migration of breast cancer cell lines.
Methods
Cell culturing and stimulation
Ductal breast cancer cell lines MCF7 and T47D (both 
ECACC, Salisbury, UK) were used for the experiments. The 
cells were cultured in DMEM (3.7 g/L NaHCO
3
, 4.5 g/L 
d-glucose, 1.028 g/L stable glutamine, and Na-pyruvate; 
Biochrom, Berlin, Germany) adding 10% heat-inactivated 
fetal calf serum (FCS; Biochrom) to the medium, and the 
solution was incubated at an atmospheric CO
2
 concentration 
of 5% and at a temperature of 37°C.
For the PCR and Western blot stimulation, MCF7 and 
T47D cells were separately grown on sterile 12 multiwell 
slides at a density of 500,000 cells/mL DMEM with 10% 
FCS. Medium was changed after 4 hours to pure DMEM 
without FCS. After 16 hours, each group of cells was stimu-
lated with 0.01 or 0.1 nM T
1
AM (Cayman Chemical, Ann 
Arbor, USA), T
3
 (Sigma-Aldrich Co., St Louis, MO, USA), 
and tetraiodothyroacetic acid (Tetrac) (Sigma-Aldrich Co.) 
for 2 hours in case of TaqMan® PCR experiments. For West-
ern blot lysates, each group of cells was stimulated with 1 




, and Tetrac for 24 hours. 10 µg/mL of 
estradiol (Sigma-Aldrich Co.) was added to T47D cells, 
which were stimulated with 10 nM T
1
AM.
Control cells were incubated under the same conditions 
without stimulants.
TaqMan® real-time PCr
The NucleoSpinRNAII (Macherey-Nagel, Düren, Germany) 
was used for RNA isolation of MCF7 and T47D cells. RNA 
samples were quantified and analyzed with the NanoPho-
tometer (Implen, Munich, Germany). Reverse transcription 
was performed using the High-Capacity cDNA reverse 
transcription kit (Thermo Fisher Scientific, Waltham, MA, 
USA) with a temperature protocol of 25°C for 10 minutes, 
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TaqMan® PCR took place in 96-well reaction plates hold-
ing a volume of 20 µL in each well. The mixture consisted 
of 1 µL of TaqMan® Gene Expression Assay 20× (Thermo 
Fisher Scientific), 10 µL of TaqMan® Universal PCR Master 
Mix 2× (Thermo Fisher Scientific), 8 µL of H
2
O (containing 
0.1% diethylpyrocarbonate (DEPC)-treated distilled water; 
Sigma-Aldrich Co.), and 1 µL of RNA sample. For the PCR 
assay, ABI Prism 7500 Fast (Thermo Fisher Scientific) was 
used with the thermal cycling conditions of 20 seconds at 
95°C, followed by 40 cycles of amplification with 3 seconds 
at 95°C and 30 seconds at 60°C. The 2−ΔΔCT method was used 
for quantification of the relative RNA expression applying 
β-actin as the housekeeping gene. Each experiment was 
validated three times (n=3).
Western blot
Stimulated and control cells were lysed for 30 minutes at 4°C 
with 200 µL buffer solution, consisting of a 1:100 dilution 
of protease inhibitor (Sigma-Aldrich Co.) in RIPA buffer 
(Sigma-Aldrich Co.). After centrifugation of the lysates with 
thermo centrifuge, a Bradford protein assay was performed 
to identify the protein amount. The proteins were separated 
according to their molecular weight using SDS-PAGE and 
transferred onto a polyvinylidenfluorid membrane (EMD 
Millipore, Billerica, MA, USA). The membrane was blocked 
for 1 hour in a receptacle consisting of 1× casein solution 
(Vector Laboratories, Burlingame, CA, USA), to prevent 
nonspecific binding of the antibodies. The primary antibodies 
anti-β-actin (clone AC-15, mouse IgG; Sigma-Aldrich Co.) 
and anti-TAAR1 (PA5-23141, rabbit IgG; Thermo Fisher 
Scientific) were equally rarefied in a 1× casein solution and 
then applied onto the membrane for 16 hours at 4°C. After-
ward, the membrane with the β-actin antibody was incubated 
with biotinylated anti-mouse IgG antibody and ABC-AmP 
reagent (both VECTASTAIN ABC-AmP Kit for rabbit IgG; 
Vector Laboratories) and the TAAR1 antibody membrane 
was incubated with biotinylated anti-rabbit IgG antibody 
and ABC-AmP reagent (both VECTASTAIN ABC-AmP 
Kit for rabbit IgG; Vector Laboratories), according to the 
manufacturer’s protocol. Staining was performed using the 
5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium 
chromogenic substrate (Vectastain ABC-AmP Kit; Vector 
Laboratories). Detection was performed with Bio-Rad Uni-
versal Hood II (Bio-Rad Laboratories Inc., Hercules, CA, 
USA), and the findings were quantified using the Quantity 
One Software (Bio-Rad Laboratories Inc,). Each Western 
blot experiment was validated nine times (n=9, three times 
in three lanes).
MTT assay
MCF7 and T47D cells were separately grown on sterile 98 
multiwell slides at a density of 10,000 cells/mL DMEM 
containing 10% FCS. The medium was changed after 4 hours 
to pure DMEM. After 16 hours, cells were stimulated for 
48 hours with 0.01, 0.1, or 10 nM T
1
AM. Control groups 
were incubated in pure DMEM or in a predilution of DMSO, 
in which T
1
AM was liquidated. After the stimulation period, 
the MTT reagent (Sigma-Aldrich Co.) was applied in order 
to specify the mitochondrial succinate-tetrazolium dehy-
drogenase system of the stimulated cells. After 30 minutes 
of incubation with MTT in the incubator, cell viability was 
measured with a multiwell spectrophotometer at a wavelength 
of 420–480 nm. Each experiment was validated three times 
(n=3).
Wound healing assay
MCF7 and T47D cells were grown on 48 multiwell plates 
at a density of 200,000 cells/mL DMEM with 10% FCS. 
After 4 hours, DMEM with FCS was substituted by pure 
DMEM and the incubation was lasted for another 20 hours 
until the well contained a confluent cell layer. Next, a straight 
line was scratched into the middle of the monolayer with a 
p100 pipet tip (Biozym, Hessisch Oldendorf, Germany). 
Afterward, the well was carefully rinsed with 1 mL of PBS 
to remove the debris and the well was again filled with pure 
DMEM. Stimulation of the cells with 10 nM T
1
AM followed 
and the control group was incubated without stimulants. The 
dish was placed in a culture incubator at 37°C and 5% CO
2
. 
Digital images of the scratch assays were taken exactly at 
0, 24, 48, 72, and 96 hours after stimulation. The recording 
contained always the same area of the scratched cells. Digital 
images were taken until the scratch was nearly closed. The 
acquired images were evaluated using the ImageJ software 
(Laboratory for Optical and Computational Instrumentation 
[LOCI] of the University of Wisconsin-Madison, Madison, 
WI, USA; http://imagej.net/). Each experiment was validated 
three times (n=3).
statistics
Data collection, processing, and analysis of statistical data 
were transacted with IBM SPSS Statistics for Windows, 
Version 22.0 (IBM Corporation, Armonk, NY, USA). A two-
sided significance level of 5% was used for all statistical tests. 
Two sample t-tests were performed for statistical analysis 
of cell culture experiments. For the real-time PCR analysis, 
we used the 2−ΔΔCT formula to calculate relative values. The 
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raw data. Therefore, the presentation of error bars is not 
applicable in this case.25
Results
Influence of T1aM, Tetrac, and T3 on 
Taar1 mrna expression in MCF7 and 
T47D breast cancer model cells
Incubation of MCF7 cells with 0.01 nM T
1
AM for 2 hours 
induced a significantly (P=0.043) increased TAAR1 mRNA 
expression compared to the control condition (Figure 1A). 
In T47D cells, 0.1 nM T
1
AM led to a significant (P=0.028) 
upregulation of TAAR1 mRNA expression after an incuba-
tion time of 2 hours (Figure 1B). The other concentrations of 
T
1
AM, which had been tested, had no significant influence 
on TAAR1 expression (Figure S1).
Tetrac induced a significant upregulation of TAAR1 
mRNA expression in MCF7 cells (P=0.017) (Figure 2A) and 
in T47D (P=0.043) (Figure 2B) after an incubation time of 
2 hours and at a concentration of 0.1 nM. Other tested con-




 had a significant influence on 
TAAR1 mRNA expression neither in MCF7 cells (P=0.249 
for 0.01 nM T
3
; P=0.345 for 0.1 nM T
3
) nor in T47D cells 
(P=0.917 for 0.01 nM T
3
; P=0.068 for 0.1 nM T
3
).
Influence of T1aM, Tetrac, and T3 on 
Taar1 protein expression in MCF7 and 
T47D breast cancer model cells
Incubation of MCF7 cells with 10 nM T
1
AM for 24 hours 
induced a significant upregulation of TAAR1 protein expres-
sion (P=0.008) (Figures 3A and 4A, B). Stimulation with 
1 nM T
1
AM did not have a significant influence on TAAR1 
expression (Figure S3). In T47D cells, no significant change 
in TAAR1 protein expression could be observed through 
the incubation with 10 nM T
1
AM for 24 hours (P=0.678) 
(Figures 3B and 4C, D).
The addition of 10 µg/mL of estradiol to T47D cells co-
stimulated with T
1
AM led to a significant upregulation of 
TAAR1 protein expression (P=0.008) (Figures 3C and 4E, 
F). TAAR1 protein expression in MCF7 and T47D cells was 
not influenced by either T
3
 or Tetrac.
Viability and migration of MCF7 and 
T47D after stimulation with T1aM and T3
MTT test
Stimulation of both cell lines (MCF7 and T47D) with 0.1 nM 
T
1
AM for 48 hours led to a significantly decreased viability 
of MCF7 cells (P=0.028) in comparison to unstimulated 
control MCF7 cells (Figure 5A). Other tested concentrations 
of T
1


























































TAAR1 mRNA expression in MCF7 cells stimulated with
0.01 nM T1AM
TAAR1 mRNA expression in T47D cells stimulated with
0.01 nM T1AM
Figure 1 TaqMan® real-time PCr in MCF7 and T47D cells after stimulation with T1aM.
Notes: (A) Bar chart as a relative representation of Taar1 mrna expression in MCF7 cells after incubation with T1aM for 2 hours detected via TaqMan
® real-time PCr. 
0.01 nM T1AM induced a significant upregulation of TAAR1 expression (P=0.043). (B) Bar chart of Taar1 mrna expression in T47D cells after incubation with T1aM for 
2 hours detected via TaqMan® real-time PCr. 0.1 nM T1AM induced a significant upregulation of TAAR1 expression (P=0.028). This bar graph shows the mean of relative 
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 at a concentration of 0.1 nM induced 
a significantly increased viability of MCF7 cells (P=0.027) 
(Figure 5B).




 could be observed in T47D 
cells.
Wound healing assay
Cell migration of MCF cells was significantly reduced 
through incubation with 10 nM T
1
AM for 12 hours 
(P=0.004) (Figure 6A) and 24 hours (P=0.016) (Figure 
6B). The scratch was closed more slowly through stimu-
lated cells in comparison to unstimulated cells (Figure 7). 
T
1
AM had no influence on the migration of T47D cells 
after 24, 48, 72, or 96 hours. No effect could be observed 
in T47D cells.
Discussion
In this study, the influence of T
3
 and thyronamines (T
1
AM) 
on TAAR1 expression has been analyzed in MCF-7 and 
T47D breast cancer cell lines. In a previous study, we found 
that TAAR1 overexpression (IRS ≥6) was favorably associ-
ated with OS in primary breast cancer; therefore, TAAR1 is 
a positive prognostic marker for OS in early breast cancer. 
Decarboxylation of thyroid hormones through the ODC leads 
to an excess of thyronamines, which presumably leads to 
the upregulation of TAAR1. Hence, the results of our MTT 
test, which detects the metabolic cell activity and showed a 
reduced cell viability of MCF7 cells through T
1
AM, are in 
line with our former findings as enhanced TAAR1 expres-
sion has a positive predictive effect on OS in breast cancer 
patients. Those findings are in line with recent results of 
Rogowski et al (2017),26 who showed that incubation of 
MCF7 cells with T
1




AM directly stimulates the G-protein-coupled 
membrane receptor TAAR1, which is expressed by breast 
cancer cells. T
1
AM can be synthetized from T
3
 through 
decarboxylation and deiodation, and also Tetrac can be 
synthesized from T
3
 through deamination. Therefore, 
there might be an indirect influence of T
3
 and Tetrac on 
the signal transduction processes stimulated by TAAR1. 
Therefore, the aim of our study was to find out a potential 
influence of T
3
 or Tetrac on T
1
AM signal transduction in 
breast cancer cells in vitro. Based on the results of our 
study, we can rule out a direct influence of T
3




TAAR1 belongs to the group of G-protein-coupled 
receptors.20 In some cases, antibodies produced against 
these targets are not very immunogenic. Therefore, Berry 
et al (2017)24 proposed that the commercially available anti-
TAAR1 antibodies are not optimal as specific antibodies for 
some of the experiments they had been employed in. In this 
study, the antibody anti-TAAR1 (PA5-23141, rabbit IgG), 


























































TAAR1 mRNA expression in MCF7 cells stimulated with
0.01 nM Tetrac
TAAR1 mRNA expression in T47D cells stimulated with
0.01 nM Tetrac
Figure 2 TaqMan® real-time PCr in MCF7 and T47D cells after stimulation with Tetrac.
Notes: (A) Bar chart of Taar1 mrna expression in MCF7 cells after incubation with Tetrac detected via TaqMan® real-time PCr. 0.1 nM Tetrac for 2 hours led to a 
significant increase in TAAR1 expression in MCF7 cells (P=0.017). (B) Bar chart of Taar1 mrna expression in T47D cells after incubation with Tetrac for 2 hours detected 
via TaqMan® Real-time PCR. 0.1 nM Tetrac induced a significant upregulation of TAAR1 expression (P=0.043). This bar graph shows the mean of relative Taar1 expression; 
therefore, the presentation of error bars is not appropriate. *P<0.05.
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be more specific in comparison to the monoclonal mouse 
IgG TAAR1 antibody (sc-514311; Santa Cruz Biotechnol-
ogy Inc., Dallas, TX, USA) and the polyclonal rabbit IgG 
antibody (ab65633; Abcam, Cambridge, UK).
In recent years, a keen research interest could be observed 
for thyroid hormone derivatives in the therapy of breast can-
cer. Bharali et al (2013)27 examined Tetrac, a thyroid hormone 
analogy of l-thyroxin, conjugated to poly(lactic-co-glycolic 
acid) nanoparticles (T-PLGA-NPs) both in vitro and in 
vivo for the treatment of drug-resistant breast cancer. They 
showed that Tetrac T-PLGA-NPs enhanced the inhibition of 
tumour-cell proliferation; and in in vivo studies, treatment 
with either Tetrac or T-PLGA-NPs resulted in a three- to 
fivefold inhibition of tumour weight.27
In our investigation, we could show that T
1
AM has a dif-
ferent effect on TAAR1 expression in MCF7 compared to 
T47D cells. T47D cells seem to function only in comparison 
to MCF7 cells after estrogen supplementation. Stimulation 
with T
1
AM induced a significant upregulation of TAAR1 
in MCF7 cells, whereas no impact could be observed for 
T
1
AM on TAAR1 expression in T47D cells. TAAR1 mRNA 
expression was significantly increased in T47D cells after 
additional co-stimulation with estradiol. Sex steroids, 
such as estrogen, regulate the growth and development of 
the mammary gland as well as the development of breast 
neoplasms.28 In vitro studies showed that stimulation with 
estrogen induces the proliferation of hormone-dependent 










































Western blot of TAAR 1 expression of T47D cells stimulated
with 10 nM T1AM
Western blot of TAAR 1 expression of MCF7 cells stimulated
with 10 nM T1AM
Western blot of TAAR 1 expression of T47D cells stimulated
with 10 nM T1AM and 10 µg/ml estradiol
0.01 nM Control 10 nM T1AM +
10 µg/ml estradiol
Figure 3 Western blot analysis of Taar1 protein expression in MCF7 and T47D cells after stimulation with T1aM.
Notes: (A) Bar chart of Taar1 expression in MCF7 cells after incubation with 10 nM T1aM for 2 hours. T1AM induced a significant upregulation of TAAR1 protein 
expression (P=0.008). (B) Bar chart of Taar1 expression in T47D cells after incubation with 10 nM T1aM and 10 µg/ml estradiol for 2 hours. T1AM led to a significant 
increase in Taar1 protein expression (P=0.008). (C) Bar chart of Taar1 expression in T47D cells after incubation with 10 nM T1AM for 2 hours. No significant change 
in Taar1 protein expression could be observed after stimulation with T1aM (P=0.678). This bar graph shows the mean of relative Taar1 expression; therefore, the 
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Figure 4 Western blot analysis of Taar1 protein expression in MCF7 and T47D cells after stimulation with T1aM.
Notes: Image of Western blot membranes with standard protein ladder (Page Ruler Prestained Protein ladder; # 26616; Thermo Fisher Scientific, Waltham, MA, USA); 
(A, C, and E) (left) Control membrane with b-actin. (B, D, and F) (right) Membrane incubated with Taar1. gray boxes mark the binding region of the Taar1 antibody 
according to its molecular weight. (A and B) nine samples of MCF7 cells: MCF7 cell control groups in columns 1), 4), and 7) and MCF7 cells stimulated with 1 nM T1aM in 
columns 2), 5), and 8) and stimulated with 10 nM T1aM in columns 3), 6), and 9). (C and D) nine samples of T47D cells: T47D cell control groups in columns 1), 4), and 7) 
and T47D cells stimulated with 1 nM T1aM in columns 2), 5), and 8) and stimulated with 10 nM T1aM in columns 3), 6), and 9). (E and F) six samples of T47D: T47D cell 
control groups in columns 1), 3), and 5) and cells stimulated with 10 nM T1aM and 10 µg/ml estradiol in columns 2), 4), and 6).
Abbreviation: T1aM, 3-iodothyronamine.






























Control 0.1 nM Control 0.1 nM
A B
Figure 5 MTT assay of MCF7 cells stimulated with T1aM and T3.
Notes: (A) Bar chart of OD of MCF7 cells after incubation with 0.1 nM T1aM for 24 hours. T1aM induced a decrease in cell proliferation (P=0.028). (B) Bar chart of OD 
of MCF7 cells after incubation with 0.1 nM T3 for 24 hours. T3 induced an increase in cell proliferation (P=0.027). This bar graph shows the mean of relative OD; therefore, 
the presentation of error bars is not appropriate.
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their expression of progesterone receptor (PR) and estrogen 
receptor (ER). MCF7 cells express a higher level of ER than 
PR, whereas T47D cells express a higher level of PR.24,25 
Estrogen in itself is able to up- or downregulate the ER. 
The direction of regulation depends on the interaction of 
the estrogen-response elements (ERE) at the DNA strand 
with the three available ER DNA promotors.29,30 As shown in 
numerous studies, estrogen leads to a downregulation of ER 
in MCF7 cells and to an upregulation of ER in T47D.26,27 This 
fact could explain the diversity of responses observed for the 
same stimulant in different breast cancer tumor cell lines.29 
Our results verify the evidence of Zaretsky et al showing 
that, for T47D cells, an exogenous additional supplement of 
estrogen is necessary to activate the expression of proteins.26 
In our case, the additional estrogen stimulation induced an 




Modulation of TAAR1 may represent a novel targeting 
strategy for breast cancer prevention and therapy. Hoefig et 
al. (2016)15 claim that one of the most important points for 
future thyronamine research is the development of a quantita-
tive assay for T
1
AM and its derivates in blood and other body 
fluids to gain a better understanding of T
1
AM metabolism and 
signal transduction. Before clinical implications are being 
considered, the complexity of the field and the technical 
challenges need to be mastered.
Aims of future studies include further investigation of 
the functional interaction between TAAR1 and the ODC in 
breast cancer tissue and cells. TAAR1 may represent a novel 
target for the prevention and treatment of breast cancer. 
Further studies are required to analyze the signaling path-
ways of the endogenous ligands of TAAR1 and to possibly 
re-examine thyroid hormone signaling in breast cancer.31
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Control 0.1 nM Control 0.1 nM
A B
Figure 6 Wound healing assay of MCF7 cells stimulated with T1aM.
Notes: (A) Bar chart of the scratch area of MCF7 cells after incubation with 10 nM T1aM for 12 hours. T1AM induced a significant downregulation of cell migration (P=0.004) 
in comparison to control cells. (B) Bar chart of the scratch area of MCF7 cells after incubation with 10 nM T1aM for 24 hours. T1AM induced a significant downregulation 














12 h 24 h
Figure 7 Wound healing assay of MCF7 control and stimulated cells.
Notes: images show cell migration into the scratch in control and stimulated cells. 
Migration of MCF7 cells is significantly inhibited through incubation with 10 nM 
T1aM for 12 hours (P=0.004). Migration of MCF7 cells is significantly inhibited 
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Control 0.01 nM 0.1 nM Control 0.01 nM 0.1 nM
*P=0.043 *P=0.028
A B
Figure S1 real-time TaqMan® PCr in MCF7- and T47D- cells after stimulation with T1aM.
Notes: (A) Bar chart as a relative representation of Taar1 mrna expression in MCF7 cells after incubation with T1aM for 2h detected via real-time TaqMan
® PCr. 
0.01nM T1AM induced a significant upregulation of TAAR1 expression (P=0.043). 0.1nM T1AM showed no significant influence on TAAR1 expression (P=0.398). (B) Bar 
chart of Taar1 mrna expression in T47D cells after incubation with T1aM for 2h detected via real-time TaqMan PCr. 0.1nM T1AM induced a significant upregulation of 
Taar1 expression (P=0.028). 0.01nM T1AM showed no significant influence on TAAR1 expression (P=0.144). This bar graph shows the mean of relative Taar1 expression; 
therefore, the presentation of error bars is not appropriate. *P<0.05.
Abbreviation: T1aM, 3-iodothyronamine.
TAAR1 mRNA expression in MCF7 cells
stimulated with Tetrac





















































Figure S2 real-time TaqMan® PCr in MCF7- and T47D- cells after stimulation with Tetrac.
Notes: (A) Bar chart of Taar1 mrna expression in MCF7 cells after incubation with Tetrac detected via real-time TaqMan® PCR. 0.1nM Tetrac for 2h led to a significant 
increase of Taar1 expression in MCF7 cells (P=0.017). 0.01nM Tetrac showed no significant influence on TAAR1 expression (P=0.345). (B) Bar chart of Taar1 mrna 
expression in T47D cells after incubation with Tetrac for 2h detected via Real-time TaqMan PCR. 0.1nM Tetrac induced a significant upregulation of TAAR1 expression 
(P=0.043). 0.01nM Tetrac showed no significant influence on TAAR1 expression (P=0.917). This bar graph shows the mean of relative Taar1 expression; therefore, the 
presentation of error bars is not appropriate. *P<0.05.
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Western blot of TAAR1 expression in MCF7 cells
stimulated with T1AM



























Control 1 nM 10 nM Control 1 nM 10 nM
A B
Figure S3 Western Blot analysis of Taar1 protein expression in MCF7 and T47D cells after stimulation with T1aM.
Notes: (A) Bar chart of TAAR1 expression in MCF7 cells after incubation with 10nM T1AM for 2h. T1AM induced a significant upregulation of TAAR1 protein expression 
(P=0.008). 1 nM T1AM showed no significant influence on TAAR1 protein expression (P=0.767). (B) Bar chart of Taar1 expression in T47D cells after incubation with 1nM 
and 10nM T1AM for 2h. No significant change in TAAR1 protein expression could be observed (1nM: P=0.441; 10nM: P=0.678). This bar graph shows the mean of relative 
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